Literature DB >> 29382514

[Epigenetic alterations in acute lymphoblastic leukemia].

María Del Pilar Navarrete-Meneses1, Patricia Pérez-Vera2.   

Abstract

Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. It is well-known that genetic alterations constitute the basis for the etiology of ALL. However, genetic abnormalities are not enough for the complete development of the disease, and additional alterations such as epigenetic modifications are required. Such alterations, like DNA methylation, histone modifications, and noncoding RNA regulation have been identified in ALL. DNA hypermethylation in promoter regions is one of the most frequent epigenetic modifications observed in ALL. This modification frequently leads to gene silencing in tumor suppressor genes, and in consequence, contributes to leukemogenesis. Alterations in histone remodeling proteins have also been detected in ALL, such as the overexpression of histone deacetylases enzymes, and alteration of acetyltransferases and methyltransferases. ALL also shows alteration in the expression of miRNAs, and in consequence, the modification in the expression of their target genes. All of these epigenetic modifications are key events in the malignant transformation since they lead to the deregulation of oncogenes as BLK, WNT5B and WISP1, and tumor suppressors such as FHIT, CDKN2A, CDKN2B, and TP53, which alter fundamental cellular processes and potentially lead to the development of ALL. Both genetic and epigenetic alterations contribute to the development and evolution of ALL.
Copyright © 2017 Hospital Infantil de México Federico Gómez. Publicado por Masson Doyma México S.A. All rights reserved.

Entities:  

Keywords:  Acute lymphoblastic leukemia; DNA methylation; Epigenetics; Epigenética; Expresión génica; Gene expression; Histone modifications; Leucemia linfoblástica aguda; Metilación del DNA; Modificaciones de histonas; miRNAs

Mesh:

Substances:

Year:  2017        PMID: 29382514     DOI: 10.1016/j.bmhimx.2017.02.005

Source DB:  PubMed          Journal:  Bol Med Hosp Infant Mex        ISSN: 0539-6115


  5 in total

1.  Wnt/β‑catenin signaling: Causes and treatment targets of drug resistance in colorectal cancer (Review).

Authors:  Gui-Xian Zhu; Dian Gao; Zhao-Zhao Shao; Li Chen; Wen-Jie Ding; Qiong-Fang Yu
Journal:  Mol Med Rep       Date:  2020-12-10       Impact factor: 2.952

2.  lncRNA HOTTIP Recruits EZH2 to Inhibit PTEN Expression and Participates in IM Resistance in Chronic Myeloid Leukemia.

Authors:  Jing Liu; Lin Yang; Xiaojun Liu; Lu Liu; Menghan Liu; Xuefeng Feng; Jianmin Luo
Journal:  Stem Cells Int       Date:  2022-09-08       Impact factor: 5.131

3.  Histone deacetylase inhibitor chidamide regulates the Wnt/β-catenin pathway by MYCN/DKK3 in B-ALL.

Authors:  Linlin Zhao; Chengfang Lv; Lili Sun; Qi Li; Yuhuang Wang; Min Wu; Yuying Wang; Zhibo Guo; Sicheng Bian; Desheng Kong; Leilei Lin; Yu Wang; Jin Zhou; Yinghua Li
Journal:  Invest New Drugs       Date:  2021-02-10       Impact factor: 3.850

4.  Thymoquinone-Induced Reactivation of Tumor Suppressor Genes in Cancer Cells Involves Epigenetic Mechanisms.

Authors:  Shahad A Qadi; Mohammed A Hassan; Ryan A Sheikh; Othman As Baothman; Mazin A Zamzami; Hani Choudhry; Abdulrahman Labeed Al-Malki; Ashwag Albukhari; Mahmoud Alhosin
Journal:  Epigenet Insights       Date:  2019-04-04

5.  KCTD15 is overexpressed in human childhood B-cell acute lymphoid leukemia.

Authors:  Giovanni Smaldone; Giuliana Beneduce; Mariarosaria Incoronato; Katia Pane; Monica Franzese; Luigi Coppola; Angela Cordella; Rosanna Parasole; Mimmo Ripaldi; Giovanni Nassa; Andrea Soricelli; Luigi Vitagliano; Peppino Mirabelli; Marco Salvatore
Journal:  Sci Rep       Date:  2019-12-27       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.